Personal information

Verified email domains

transcriptomics, genomics, cardiovascular disease, microRNA therapeutics, metatranscriptomics, cardiothoracic genomics, obesity, type 2 diabetes, infective endocarditis, phage therapy
Australia

Biography

I hold a Bachelor of Science in Zoology and a Masters of Science (1st class Hons) in Molecular and Cellular Biology from the University of Canterbury, New Zealand. Additionally, I obtained a PhD in Medicine from the University of Sydney in 2003. My research experience includes working in the field of transcriptomics in ageing, obesity, and cardiovascular diseases at the Ramaciotti Centre for Genomics, University of NSW, as well as in cancer biology at the Asbestos Diseases Research Institute. I have also worked in the healthcare sector as a senior consultant specializing in medical writing.

Throughout my career, I have received prestigious fellowships, including the NHMRC Peter Doherty fellowship (2005-8) and the University of NSW Vice-Chancellor Research Fellowship (2009-2014), which are considered tier 1 fellowships in Australia.

I was appointed as a conjoint Associate Professor at the University of NSW in January 2016 in recognition of my significant contributions to research, teaching, mentoring, and administrative management. In 2015, I was awarded a scholarship to participate in the Women In Leadership course through the Global Leadership Initiative.

As a Chief Investigator, I have successfully secured three NHMRC project grants in the field of transcriptomics and cardiovascular disease. These projects focused on identifying biomarkers in atrial fibrillation, myocardial infarction, and utilising microRNA therapeutics to restore cardiac function. I have obtained over AUD $19 million in external and internal competitive research and equipment funding, including grants from various organisations and institutions, and philanthropy foundations.

Currently, I am the business development lead and co-Deputy Director of Phage Australia, managing the national and international networks in biobanking, diagnostics, therapeutics, and genomics to combat antimicrobial resistance. I have also served as the president of the Australasian Genomic Technologies Association and remain a managing executive member of AGTA. In addition, I hold positions as the Genomic Chair for the Scientific Advisory Committee at Westmead Research Precinct and was a former member of the GEDI committee at AAMRI.

In addition to my accomplishments, I have a prolific publication record with over 120 publications in peer-reviewed journals. Notably, 80% of these publications have received editorial and media coverage, and some have associated patent cooperation treaties (PCTs). My research has garnered significant attention, as evidenced by an h-index of 39 and over 7,000 citations.

Education, mentoring, and career development are important aspects of my work, and I actively contribute to these areas. I have joined the Board of Directors of an independent school in Sydney, Australia, as a pro bono member, as part of my commitment to the community.

Activities

Employment (12)

Westmead Institute for Medical Research: Sydney, NSW, AU

2021-06-15 to present | Deputy Director (Phage Australia)
Employment
Source: Self-asserted source
Ruby CY Lin

Westmead Institute for Medical Research: Sydney, NSW, AU

2021-01-01 to present | Business Development Lead (Centre for Infectious Diseases and Microbiology)
Employment
Source: Self-asserted source
Ruby CY Lin

MacLin Consulting: Sydney, NSW, AU

2016-04-11 to present | Career Coach, Science Communicator, Medical Writer
Employment
Source: Self-asserted source
Ruby CY Lin

Torrens University Australia: Adelaide, South Australia, AU

2021-01-01 to 2025-12-31 | Adjunct Professor (honorary) (Centre for Healthy Futures)
Employment
Source: Self-asserted source
Ruby CY Lin

University of New South Wales: Sydney, NSW, AU

2020-08-01 to 2023-07-31 | Adjunct Associate Professor (honorary) (School of Medical Sciences)
Employment
Source: Self-asserted source
Ruby CY Lin

Westmead Institute for Medical Research: Sydney, New South Wales, AU

2017-10-24 to 2020-12-31 | Project Manager/ Conjoint Professor of Genomics (Centre for Infectious Diseases and Microbiology)
Employment
Source: Self-asserted source
Ruby CY Lin

University of New South Wales: Sydney, NSW, AU

2016-01-01 to 2020-07-31 | Conjoint Associate Professor (School of Medical Sciences)
Employment
Source: Self-asserted source
Ruby CY Lin

Asbestos Diseases Research Institute: Sydney, NSW, AU

2014-05-12 to 2016-12-09 | Senior Research Fellow
Employment
Source: Self-asserted source
Ruby CY Lin

University of New South Wales: Sydney, NSW, AU

2014-05 to 2015-12-31 | Adjunct Senior Lecturer (School of Biotechnology & Biomolecular Sciences)
Employment
Source: Self-asserted source
Ruby CY Lin

University of New South Wales: Sydney, NSW, AU

2009-01-01 to 2014-04-04 | UNSW Vice-Chancellor Post-doctoral Research Fellow (School of Biotechnology & Biomolecular Sciences, Ramaciotti Centre for Genomics)
Employment
Source: Self-asserted source
Ruby CY Lin

University of New South Wales: Sydney, NSW, AU

2005 to 2008 | NHMRC Peter Doherty Postdoctoral Research Fellow (School of Biotechnology & Biomolecular Sciences)
Employment
Source: Self-asserted source
Ruby CY Lin

University of New South Wales: Sydney, NSW, AU

2003 to 2005 | Postdoctoral Research Scientist (Ramaciotti Centre for Genomics)
Employment
Source: Self-asserted source
Ruby CY Lin

Education and qualifications (3)

University of Sydney: Sydney, NSW, AU

1998-06-08 to 2002-04-01 | PhD (Bosche Institute, Physiology)
Education
Source: Self-asserted source
Ruby CY Lin

University of Canterbury: Christchurch, NZ

1995 to 1997 | MSc (Hons) Molecular & Cellular Biology
Education
Source: Self-asserted source
Ruby CY Lin

University of Canterbury: Christchurch, NZ

1992 to 1994 | BSc Zoology
Education
Source: Self-asserted source
Ruby CY Lin

Professional activities (6)

Westmead Institute for Medical Research: Sydney, NSW, AU

2021-05-04 to present | Deputy Director (Phage Australia)
Invited position
Source: Self-asserted source
Ruby CY Lin

Westmead Institute for Medical Research: Sydney, New South Wales, AU

2020-08-01 to present | Genomic Chair (Westmead Research Precinct Scientific Advisory Committee)
Service
Source: Self-asserted source
Ruby CY Lin

Westmead Institute for Medical Research: Sydney, New South Wales, AU

2020-08-01 to present | Committee member (Scientific Advisory Committee (Biobanking))
Service
Source: Self-asserted source
Ruby CY Lin

Australasian Genomic Technologies Association: Melbourne, AU

2003-01-01 to present | Executive Member
Membership
Source: Self-asserted source
Ruby CY Lin

Australasian Genomic Technologies Association: Sydney, NSW, AU

2019-10-20 to 2023-03-17 | Vice President
Service
Source: Self-asserted source
Ruby CY Lin

Association of Australian Medical Research Institutes: Sydney, AU

2021 to 2023-02-27 | Gender Equality Diversity Inclusion Committee
Membership
Source: Self-asserted source
Ruby CY Lin

Funding (19)

Hooper Shaw Foundation - sustainable phage therapy service

2024-01 to 2026-12 | Grant
Hooper Shaw Foundation (Sydney, NSW, AU)
Source: Self-asserted source
Ruby CY Lin

Therapeutic monitoring during phage therapy

2023-12 to 2024-12 | Grant
Dooleys Lidcombe Catholic Club (Sydney, NSW, AU)
Source: Self-asserted source
Ruby CY Lin

Ensure Sovereign Manufacture of Phage Therapy

2023-07 to 2025-07 | Grant
Office of Health and Medical Research, NSW State Government (Sydney, NSW, AU)
Source: Self-asserted source
Ruby CY Lin

Phage Therapy Education Package

2021-08 to 2022-08 | Grant
Office of Health and Medical Research, NSW State Government (Sydney, NSW, AU)
Source: Self-asserted source
Ruby CY Lin

Phage Australia - Integrating Australian Phage Biobanking and Therapeutic Networks and Delivering Solutions for Antimicrobial Resistance

2021-07 to 2022-12 | Grant
Medical Research Future Fund (ACT, ACT, AU)
GRANT_NUMBER:

RFRHPI000017

Source: Self-asserted source
Ruby CY Lin

Phage Production Infrastructure

2021-06 to 2022-06 | Grant
Office of Health and Medical Research, NSW State Government (Sydney, NSW, AU)
Source: Self-asserted source
Ruby CY Lin

MGI/Decode Science/Micromon Genomics Next Generation Sequencing Research Grant 2019

2019-07 to 2020-07 | Grant
BGI (Sydney, NSW, AU)
GRANT_NUMBER: 0
Source: Self-asserted source
Ruby CY Lin

WMPhi001 - Compassionate use treatment of severe Staphylococcus aureus infections with bacteriophage therapy

2018-03 to 2019-03 | Grant
AmpliPhi Biosciences (San Diego, US, US)
Source: Self-asserted source
Ruby CY Lin

Modelling A Novel Disease Mechanism for Distal Hereditary Motor Neuropathy (DHMN1) on chromosome 7 using Induced Pluripotent Stem Cell (iPSC) Technology.

2016-07 to present | Grant
CMT Association of Australia (Sydney, AU)
Source: Self-asserted source
Ruby CY Lin

Induced Pluripotent Stem Cells (iPSC): a program to introduce iPSC technologies to study hereditary neuropathy gene mutations in motor neuron cell models.

2016-06 to 2017-06 | Grant
Philip Bushell Foundation (Sydney, Asia-Pacific, AU)
Source: Self-asserted source
Ruby CY Lin

circular RNAs (circRNAs): novel biomarkers for early detection of malignant pleural mesothelioma

2016-01 to 2017-01 | Grant
Slater and Gordon Health and Research project fund (Sydney, AU)
Source: Self-asserted source
Ruby CY Lin

Expanding the Asbestos Diseases Research Institute (ADRI) biobank to create a state-wide repository for research into thoracic cancers

2015-09 to 2016-09 | Grant
Cancer Institute NSW (NSW, NSW, AU)
Source: Self-asserted source
Ruby CY Lin

Expanding Basic, Clinical and Functional Genomic Cancer Research at Concord Campus

2015-07 to 2016-07 | Grant
CI NSW REG (NSW, NSW, AU)
GRANT_NUMBER: 15/REG/1-16
Source: Self-asserted source
Ruby CY Lin

Targeting small non-coding RNAs to restore cardiac function.

2013 to 2015 | Grant
National Health and Medical Research Council (ACT, ACT, AU)
GRANT_NUMBER:

1045144

Source: Self-asserted source
Ruby CY Lin

Targeting PI3K-regulated microRNAs to treat heart failure

2010 to 2012 | Grant
National Health and Medical Research Council (ACT, ACT, AU)
GRANT_NUMBER:

586603

Source: Self-asserted source
Ruby CY Lin

Targeting PI3K-regulated microRNAs to treat heart failure

2009-01 to 2014-04 | Salary award
University of New South Wales (NSW, NSW, AU)
Source: Self-asserted source
Ruby CY Lin

Investigating effect of ageing using transcriptomic technologies

2005-01 to 2008-12 | Salary award
National Health and Medical Research Council (ACT, ACT, AU)
GRANT_NUMBER:

351012

Source: Self-asserted source
Ruby CY Lin

Identifying biomarkers in atrial fibrillation

2005 to 2007 | Grant
National Health and Medical Research Council (ACT, ACT, AU)
GRANT_NUMBER:

136533

Source: Self-asserted source
Ruby CY Lin

Tissue microarrayer to enable pathological studies of cancer

2005 to 2006 | Grant
Cancer Council NSW (NSW, NSW, AU)
Source: Self-asserted source
Ruby CY Lin

Works (50 of 95)

Items per page:
Page 1 of 2

Reduced PI3K(p110α) induces atrial myopathy, and PI3K-related lipids are dysregulated in athletes with atrial fibrillation.

Journal of sport and health science
2025-01-16 | Journal article
Contributors: Bass-Stringer S; Bernardo BC; Yildiz GS; Matsumoto A; Kiriazis H; Harmawan CA; Tai CMK; Chooi R; Bottrell L; Ezeani M et al.
Source: Self-asserted source
Ruby CY Lin

Policy in practice: Cystic Fibrosis Australia and Phage Australia surveys: understanding clinical needs and attitudes towards phage therapy in the cystic fibrosis community

Sustainable Microbiology
2025-01-09 | Journal article
Contributors: Stephanie Lynch; Holly Sinclair; Ameneh Khatami; Nicki Mileham; Jessica C Sacher; Jan Zheng; Ruby C Y Lin; Jonathan Iredell
Source: check_circle
Crossref

Phage Therapy in Korea: A Prescribers' Survey of Attitudes Amongst Korean Infectious Diseases Specialists Towards Phage Therapy

Infection & Chemotherapy
2024 | Journal article
Contributors: Shinwon Lee; Stephanie Lynch; Ruby C Y Lin; Heejoon Myung; Jonathan R Iredell
Source: check_circle
Crossref

Cystic Fibrosis Australia and Phage Australia survey: Understanding clinical needs and attitudes towards phage therapy in the CF community

2024-05-16 | Preprint
Contributors: Stephanie Lynch; Holly Sinclair; Ameneh Khatami; Nicki Mileham; Jessica C Sacher; Jan Zheng; Ruby CY Lin; Jonathan Iredell
Source: check_circle
Crossref

Mammalian cells internalize bacteriophages and use them as a resource to enhance cellular growth and survival

PLOS Biology
2023-10-26 | Journal article
Part of ISSN: 1545-7885
Contributors: Marion C. Bichet; Jack Adderley; Laura Avellaneda-Franco; Isabelle Magnin-Bougma; Natasha Torriero-Smith; Linden J. Gearing; Celine Deffrasnes; Cassandra David; Genevieve Pepin; Michael P. Gantier et al.
Source: Self-asserted source
Ruby CY Lin

Phage Therapy in Korea: a Prescribers' Survey of Attitudes amongst Korean Infectious Diseases Specialists towards phage therapy

Infection and Chemotherapy (in press)
2023-08-23 | Journal article | Conceptualization, Funding acquisition
Contributors: Shinwon Lee; Stephanie Lynch; Ruby CY Lin; Heejoon Myung; Jonathan R Iredell
Source: Self-asserted source
Ruby CY Lin

Refractory Pseudomonas aeruginosa infections treated with phage PASA16: A compassionate use case series

Med
2023-08-09 | Journal article
Part of ISSN: 2666-6340
Contributors: Hadil Onallah; Ronen Hazan; Ran Nir-Paz; Michael J. Brownstein; Joseph R. Fackler; Bri’Anna Horne; Robert Hopkins; Subhendu Basu; Ortal Yerushalmy; Sivan Alkalay-Oren et al.
Source: Self-asserted source
Ruby CY Lin

Attitudes to phage therapy among Australian infectious diseases physicians

2023-07-06 | Preprint
Contributors: Martin Plymoth; Stephanie A. Lynch; Ameneh Khatami; Holly A. Sinclair; Jessica C. Sacher; Jan Zheng; Ruby CY. Lin; Jonathan R. Iredell
Source: check_circle
Crossref

Mammalian cells internalize bacteriophages and utilize them as a food source to enhance cellular growth and survival

2023-03-11 | Preprint
Contributors: Marion C. Bichet; Jack Adderley; Laura Avellaneda; Linden J. Gearing; Celine Deffrasnes; Cassandra David; Genevieve Pepin; Michael P. Gantier; Ruby CY Lin; Ruzeen Patwa et al.
Source: check_circle
Crossref

Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): protocol for an open-label, single-arm trial

BMJ Open
2022-12 | Journal article
Contributors: Ameneh Khatami; David A Foley; Morgyn S Warner; Elizabeth H Barnes; Anton Y Peleg; Jian Li; Stephen Stick; Nettie Burke; Ruby C Y Lin; Julia Warning et al.
Source: check_circle
Crossref

Novel gene-intergenic fusion involving ubiquitin E3 ligase UBE3C causes distal hereditary motor neuropathy

Brain
2022-11-16 | Journal article
Part of ISSN: 0006-8950
Part of ISSN: 1460-2156
Contributors: Ruby CY Lin; Anthony N Cutrupi; Ramesh Narayanan; Gonzalo Perez-Siles; Bianca R Grosz; Kaitao Lai; Alexandra Boyling; Melina Ellis; Ruby C Y Lin; Brent Neumann et al.
Source: Self-asserted source
Ruby CY Lin

3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies

Frontiers in Oncology
2022-08-26 | Journal article
Part of ISSN: 2234-943X
Contributors: Ruby CY Lin; Huaikai Shi; Emma M. Rath; Ruby C. Y. Lin; Kadir Harun Sarun; Candice Julie Clarke; Brian C. McCaughan; Helen Ke; Anthony Linton; Kenneth Lee et al.
Source: Self-asserted source
Ruby CY Lin

Novel gene-intergenic fusion involving ubiquitin E3 ligase UBE3C causes distal hereditary motor neuropathy: A new mechanism for motor neuron degeneration

2022-08-17 | Preprint
Contributors: Anthony N. Cutrupi; Ramesh K. Narayanan; Gonzalo Perez-Siles; Bianca R. Grosz; Kaitao Lai; Alexandra Boyling; Melina Ellis; Ruby CY Lin; Brent Neumann; Di Mao et al.
Source: check_circle
Crossref

Two plus One: Combination Therapy Tri-systems Involving Two Membrane-Disrupting Antimicrobial Macromolecules and Antibiotics

ACS Infectious Diseases
2022-08-12 | Journal article
Contributors: Zeyu Shao; Erna Wulandari; Ruby C. Y. Lin; Jiangtao Xu; Kang Liang; Edgar H. H. Wong
Source: check_circle
Crossref

Data to Power Precision Phage Therapy: A Look at the Phage Directory–Phage Australia Partnership

PHAGE
2022-06-01 | Journal article
Part of ISSN: 2641-6530
Part of ISSN: 2641-6549
Contributors: Ruby CY Lin; Jessica C. Sacher; Jan Zheng; Ruby C.Y. Lin
Source: Self-asserted source
Ruby CY Lin

Bacterial lysis, autophagy and innate immune responses during adjunctive phage therapy in a child

EMBO Molecular Medicine
2021-09-07 | Journal article
Contributors: Ameneh Khatami; Ruby C Y Lin; Aleksandra Petrovic‐Fabijan; Sivan Alkalay‐Oren; Sulaiman Almuzam; Philip N Britton; Michael J Brownstein; Quang Dao; Joe Fackler; Ronen Hazan et al.
Source: check_circle
Crossref

Phage Biobank: Present Challenges and Future Perspectives

Current Opinion in Biotechnology
2021-04 | Journal article
Contributors: Ruby CY Lin; Jessica C Sacher; Pieter-Jan Ceyssens; Jan Zheng; Ali Khalid; Jonathan R Iredell
Source: check_circle
Crossref

Transcriptome analysis of islets from diabetes-resistant and diabetes-prone obese mice reveals novel gene regulatory networks involved in beta cell compensation and failure

FASEB J
2021-04-06 | Journal article
Source: Self-asserted source
Ruby CY Lin

A phage therapy guide for clinicians and basic scientists: background and highlighting applications for developing countries

Frontiers in Microbiology
2021-02-11 | Journal article
Contributors: Ali Khalid; Ruby CY Lin; Jonathan Iredell
Source: Self-asserted source
Ruby CY Lin

Skeletal glucocorticoid signalling determines leptin resistance and obesity in aging mice

Molecular Metabolism
2020-12 | Journal article
Part of ISSN: 2212-8778
Source: Self-asserted source
Ruby CY Lin

Therapeutic monitoring of the host-bacterium-phage interaction in a child

2020-11-19 | Other
Contributors: Ameneh Khatami; Ruby Lin; Aleksandra Petrovic-Fabijan; Sivan Alkalay-Oren; Sulaiman Almuzam; Philip Britton; Michael Brownstein; Quang Dao; Joseph Fackler; Ronen Hazan et al.
Source: check_circle
Crossref

Vascular transcriptome landscape of Trail−/− mice: Implications and therapeutic strategies for diabetic vascular disease

The FASEB Journal
2020-06-05 | Journal article
Source: Self-asserted source
Ruby CY Lin

Characterizing the role of porin mutations in susceptibility of beta lactamase producing Klebsiella pneumoniae isolates to ceftaroline and ceftaroline-avibactam

International Journal of Infectious Diseases
2020-04 | Journal article
Part of ISSN: 1201-9712
Source: Self-asserted source
Ruby CY Lin

Publisher Correction: Safety of bacteriophage therapy in severe Staphylococcus aureus infection

Nature Microbiology
2020-03-05 | Journal article
Contributors: Aleksandra Petrovic Fabijan; Ruby C. Y. Lin; Josephine Ho; Susan Maddocks; Nouri L. Ben Zakour; Jonathan R. Iredell; Ali Khalid; Carola Venturini; Richard Chard; Sandra Morales et al.
Source: check_circle
Crossref

Safety of bacteriophage therapy in severe Staphylococcus aureus infection

Nature Microbiology
2020-02-17 | Journal article
Contributors: Aleksandra Petrovic Fabijan; Ruby C. Y. Lin; Josephine Ho; Susan Maddocks; Nouri L. Ben Zakour; Jonathan R. Iredell; Ali Khalid; Carola Venturini; Richard Chard; Sandra Morales et al.
Source: check_circle
Crossref

Phage therapy for severe bacterial infections: a narrative review

Medical Journal of Australia
2019-10-06 | Journal article
Source: Self-asserted source
Ruby CY Lin

Polyclonal Staphylococcus aureus Bacteremia

Annals of Internal Medicine
2019-09-17 | Journal article
Part of ISSN: 0003-4819
Source: Self-asserted source
Ruby CY Lin

Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa

American Journal of Respiratory and Critical Care Medicine
2019-08-20 | Journal article
Source: Self-asserted source
Ruby CY Lin

State of the regulatory affair: Regulation of phage therapy in Australia

Phage Directory
2019-08-16 | Research protocol or technique
Source: Self-asserted source
Ruby CY Lin

Safety and Tolerability of Bacteriophage Therapy in Severe Staphylococcus aureus Infection

2019-04-26 | Other
Contributors: Aleksandra Petrovic Fabijan; Ruby CY Lin; Josephine Ho; Susan Maddocks; Jonathan R Iredell
Source: check_circle
Crossref

Bacteriophage therapy for severe infections

Microbiology Australia
2019-02-18 | Journal article
Source: Self-asserted source
Ruby CY Lin

Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases

Cold Spring Harbour Molecular Case studies
2019-02-11 | Journal article
Source: Self-asserted source
Ruby CY Lin

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.

Carcinogenesis
2018-04 | Journal article
Contributors: Schelch K; Wagner C; Hager S; Pirker C; Siess K; Lang E; Lin R; Kirschner MB; Mohr T; Brcic L et al.
Source: Self-asserted source
Ruby CY Lin via Europe PubMed Central

Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
2017-11 | Journal article
Contributors: Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC et al.
Source: Self-asserted source
Ruby CY Lin via Europe PubMed Central

Loss of the vitamin D receptor in human breast and prostate cancers strongly induces cell apoptosis through downregulation of Wnt/β-catenin signaling.

Bone research
2017-09 | Journal article
Contributors: Zheng Y; Trivedi T; Lin RC; Fong-Yee C; Nolte R; Manibo J; Chen Y; Hossain M; Horas K; Dunstan C et al.
Source: Self-asserted source
Ruby CY Lin via Europe PubMed Central

Replicable Expansion and Differentiation of Neural Precursors from Adult Canine Skin.

Stem cell reports
2017-08 | Journal article
Contributors: Duncan T; Lowe A; Sidhu K; Sachdev P; Lewis T; Lin RCY; Sytnyk V; Valenzuela M
Source: Self-asserted source
Ruby CY Lin via Europe PubMed Central

Sex differences in response to miRNA‐34a therapy in mouse models of cardiac disease: identification of sex‐, disease‐ and treatment‐regulated miRNAs

The Journal of Physiology
2016-10-15 | Journal article
Contributors: Bianca C. Bernardo; Jenny Y. Y. Ooi; Aya Matsumoto; Yow Keat Tham; Saloni Singla; Helen Kiriazis; Natalie L. Patterson; Junichi Sadoshima; Susanna Obad; Ruby C. Y. Lin et al.
Source: check_circle
Crossref

MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients

Genomics Data
2016-06-20 | Report
Source: Self-asserted source
Ruby CY Lin
grade
Preferred source (of 2)‎

KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma

Molecular Cancer
2016-06-01 | Journal article
Source: Self-asserted source
Ruby CY Lin
grade
Preferred source (of 2)‎

Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseases

RNA Biology
2016-04-28 | Journal article
Source: Self-asserted source
Ruby CY Lin

Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure Overload

Scientific Reports
2016-03-01 | Journal article
Source: Self-asserted source
Ruby CY Lin

Identification of novel cardioprotective miRNAs and mRNAs regulated by miR-34

Heart, Lung and Circulation
2015 | Conference paper
Source: Self-asserted source
Ruby CY Lin

miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.

2015-09 | Journal article
Contributors: Williams M; Kirschner MB; Cheng YY; Hanh J; Weiss J; Mugridge N; Wright CM; Linton A; Kao SC; Edelman JJ et al.
Source: Self-asserted source
Ruby CY Lin via Europe PubMed Central

miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart.

Future Medicinal Chemistry
2015-09-24 | Journal article
Source: Self-asserted source
Ruby CY Lin

Human induced pluripotent stem cells derived from a patient with sporadic Alzheimer’s disease exhibit altered neuronal proliferative capacity

J Stem Cell Clin Pract
2015-03 | Journal article
Source: Self-asserted source
Ruby CY Lin

Identification Of miRNA-34 Networks In Pathological Cardiac Remodeling

Circulation Research
2014 | Conference paper
Source: Self-asserted source
Ruby CY Lin

MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma

Molecular Oncology
2014 | Journal article
Source: Self-asserted source
Ruby CY Lin

O166 Inhibition of miRNA-652 Using LNA-antimiRs Improves Cardiac Function in a Mouse Model of Pressure Overload and is Associated with Preserved Angiogenesis and Upregulation of Jagged 1

Global Heart
2014 | Conference paper
Source: Self-asserted source
Ruby CY Lin

Paternal high-fat diet consumption induces common changes in the transcriptomes of retroperitoneal adipose and pancreatic islet tissues in female rat offspring

The FASEB Journal
2014 | Journal article
Source: Self-asserted source
Ruby CY Lin

PT353 Identification of miRNA networks in pathological cardiac remodelling-New therapeutic targets

Global Heart
2014 | Conference paper
Source: Self-asserted source
Ruby CY Lin
Items per page:
Page 1 of 2

Peer review (6 reviews for 3 publications/grants)

Review activity for BMC pulmonary medicine (2)
Review activity for International journal of antimicrobial agents. (3)
Review activity for International journal of molecular sciences. (1)